The FDA will review an application to consider potential approval of Nubeqa plus androgen deprivation therapy for metastatic ...

Dubbed Nubeqa but known generically as darolutamide, the treatment comes in combination with androgen deprivation therapy ...

Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for ...

The CAPItello-281 trial aimed to assess the safety and efficacy of Truqap in combination with abiraterone and ADT.

Data from a late-stage study shows that treatment with a three-drug combo involving AZN's Truqap benefits patients with an ...

AstraZeneca announced positive results from a phase three prostate cancer trial on Monday, reporting that its AKT inhibitor ...

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate ...

UK pharma major AstraZeneca today released positive high-level results from the CAPItello-281 Phase III trial showing that ...

The following is a summary of “High 11-ketotestosterone linked to shorter time to castration resistance in recurrent ...

Results from the CAPItello-281 Phase III trial showed that AstraZeneca’s (AZN) Truqap in combination with abiraterone and androgen deprivation ...

Bayer (BAYRY) announced that the FDA has accepted the company’s supplemental new drug application, or sNDA, for the oral androgen receptor ...

AstraZeneca (AZN) reported positive results from a Phase 3 study of its drug Truqap in the treatment of a certain type of ...